Cleve Clin J Med. 2025 Mar 3;92(3):152-158. doi: 10.3949/ccjm.92a.24089.ABSTRACTHospital admissions for diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS), the most severe hyperglycemic emergencies in patients with diabetes, have increased considerably over the past decade. The p
Cleve Clin J Med. 2025 Feb 3;92(2):103-108. doi: 10.3949/ccjm.92a.24033.ABSTRACTBariatric procedures have been shown to decrease mortality in patients with obesity and even induce remission of type 2 diabetes, hypertension, hyperlipidemia, and obstructive sleep apnea. One common complication of bari
Cleve Clin J Med. 2025 Jan 2;92(1):53-61. doi: 10.3949/ccjm.92a.24011.ABSTRACTMore and more patients with atrial fibrillation are undergoing catheter ablation as a rhythm-control strategy, but the recurrence rate after the procedure is high. A wide array of risk factors contribute to the pathogenesi
Cleve Clin J Med. 2025 Jan 2;92(1):33-39. doi: 10.3949/ccjm.92a.24075.ABSTRACTDiabetic ketoacidosis (DKA) was historically considered a condition typical of type 1 diabetes. However, patients with type 2 diabetes may present with DKA, usually with higher blood glucose levels and milder ketoacidosis.
Cleve Clin J Med. 2024 Oct 1;91(10):611-620. doi: 10.3949/ccjm.91a.23090.ABSTRACTAccess to and use of glycemic data are central to optimal management of diabetes. Use of continuous glucose monitoring (CGM) data to guide the management of diabetes has increased dramatically thanks to improved ease of
Cleve Clin J Med. 2024 Aug 1;91(8):503-510. doi: 10.3949/ccjm.91a.24028.ABSTRACTInternists are integral in the multidisciplinary approach to diabetic retinopathy, contributing significantly to the management of diabetes and diabetes-related complications. Effective screening processes, timely referr
No abstractCleve Clin J Med. 2024 Jul 1;91(7):392-393. doi: 10.3949/ccjm.91b.07024.NO ABSTRACTPMID:38950980 | DOI:10.3949/ccjm.91b.07024
Cleve Clin J Med. 2024 Jun 3;91(6):353-360. doi: 10.3949/ccjm.91a.23073.ABSTRACTDiabetes technology is evolving rapidly and is changing the way both patients and clinicians approach the management of diabetes. With more devices gaining US Food and Drug Administration approval and insurance coverage
Cleve Clin J Med. 2024 Jun 3;91(6):373-383. doi: 10.3949/ccjm.91a.23078.ABSTRACTGastroparesis is a heterogeneous motility disorder characterized by nausea, vomiting, and postprandial fullness. Its diagnosis requires objective documentation of delayed gastric emptying of solid food and exclusion of m
No abstractCleve Clin J Med. 2024 Apr 1;91(4):213-214. doi: 10.3949/ccjm.91a.23074.NO ABSTRACTPMID:38561213 | DOI:10.3949/ccjm.91a.23074
No abstractCleve Clin J Med. 2023 Dec 1;90(12):721-722. doi: 10.3949/ccjm.90a.23046.NO ABSTRACTPMID:38040439 | DOI:10.3949/ccjm.90a.23046
Cleve Clin J Med. 2023 Oct 2;90(10):615-618. doi: 10.3949/ccjm.90a.23049.ABSTRACTHyperglycemia is common in hospitalized patients and is traditionally managed with scheduled and correctional doses of insulin. The authors present an overview of the latest (2022) guidelines from the Endocrine Society
No abstractCleve Clin J Med. 2023 Sep 1;90(9):545-548. doi: 10.3949/ccjm.90a.22096.NO ABSTRACTPMID:37657834 | DOI:10.3949/ccjm.90a.22096
No abstractCleve Clin J Med. 2023 Jan 3;90(1):13-14. doi: 10.3949/ccjm.90b.01023.NO ABSTRACTPMID:36596603 | DOI:10.3949/ccjm.90b.01023
Cleve Clin J Med. 2023 Jan 3;90(1):53-62. doi: 10.3949/ccjm.90a.22069.ABSTRACTData have been accumulating on the risk of developing type 2 diabetes in patients receiving statins and on the potential adverse effects of these drugs on glycemic control in patients who already have type 2 diabetes. This
No abstractCleve Clin J Med. 2022 Oct 3;89(10):597.NO ABSTRACTPMID:36192028
Cleve Clin J Med. 2022 Aug 1;89(8):457-464. doi: 10.3949/ccjm.89a.21110.ABSTRACTGlucagon-like peptide-1 (GLP-1) receptor agonists improve glycemic control in patients with type 2 diabetes mellitus, have cardioprotective and renoprotective effects, and do not cause weight gain or significant hypoglyc
Cleve Clin J Med. 2022 Apr 1;89(4):191-199. doi: 10.3949/ccjm.89a.20171.ABSTRACTHyperglycemia is associated with poor clinical outcomes in critically ill patients. Initial clinical trials of intensive insulin therapy targeting blood glucose levels of 80 to 110 mg/dL showed improved outcomes, but sub
No abstractCleve Clin J Med. 2021 Nov 2;88(11):588-589. doi: 10.3949/ccjm.88b.11021.NO ABSTRACTPMID:34728481 | DOI:10.3949/ccjm.88b.11021
Cleve Clin J Med. 2021 Oct 1;88(10):547-555. doi: 10.3949/ccjm.88a.20121.ABSTRACTThe jury is still out on whether a low-carbohydrate, ketosis-inducing diet is an effective and safe adjunctive therapy to insulin in type 1 diabetes. The limited published literature reports an association with weight l
Cleve Clin J Med. 2021 May 3;88(5):295-303. doi: 10.3949/ccjm.88a.20115.ABSTRACTCoronary revascularization has matured as a field since coronary artery bypass grafting (CABG) was first developed over 50 years ago, with diagnostic and treatment methods having advanced dramatically. CABG remains the s
No abstractCleve Clin J Med. 2021 Apr 1;88(4):205.NO ABSTRACTPMID:33795249
Cleve Clin J Med. 2021 Jan 1;88(1):47-58. doi: 10.3949/ccjm.88a.20088.ABSTRACTSodium-glucose cotransporter-2 (SGLT-2) inhibitors are an exceptionally versatile class of medication, and their glycemic and nonglycemic benefits could help millions of patients with type 2 diabetes. Of note, they have be
Cleve Clin J Med. 2020 Jun 30;87(7):384-388. doi: 10.3949/ccjm.87a.ccc013.ABSTRACTInformation about the clinical presentation and course of COVID-19 is evolving rapidly. On presentation, cough and fever predominate, but extrapulmonary symptoms are also common; in some patients, loss of sense of smel
